牛-人重配五价轮状病毒疫苗ROTASIIL®与已上市轮状病毒疫苗对婴儿疫苗免疫原性无干扰的比较
在印度一项III期多中心开放标签随机对照研究中,1500名健康婴儿随机接受三剂BRV-PV或两剂Rotarix®加一剂安慰剂,同时接种DTwP-HepB-Hib、口服脊灰疫苗和灭活脊灰疫苗。结果显示BRV-PV组与Rotarix®组针对白喉、破伤风、乙肝、Hib、脊灰1型和3型的血清保护率差异均小于1%,抗百日咳IgG几何平均浓度比值为1.04(90%CI 0.90;1.19)。结论认为BRV-PV不干扰同时接种的常规婴儿疫苗的免疫原性。
要点
- BRV-PV组与Rotarix®组对白喉、破伤风、乙肝、Hib、脊灰1型和3型的血清保护率差异均小于1%。
- 抗百日咳IgG几何平均浓度比值BRV-PV组 vs Rotarix®组为1.04(90%CI 0.90;1.19)。
- BRV-PV不干扰同时接种的常规婴儿疫苗的免疫原性。
核心结论
- BRV-PV不干扰同时接种的常规婴儿疫苗的免疫原性。
研究设计与样本
- III期、多中心、开放标签、随机对照研究,在印度纳入1500名健康婴儿,随机分为BRV-PV组(1125名)和Rotarix®组(375名),其中1341名按方案完成研究。
- 婴儿在6、10、14周龄时接种三剂BRV-PV或两剂Rotarix®加一剂安慰剂,同时接种三剂DTwP-HepB-Hib和口服脊灰疫苗,14周龄时接种单剂灭活脊灰疫苗,末次接种后4周采集血样评估免疫应答。
主要发现
- 两组中超过97%的受试者针对白喉、破伤风、乙肝、Hib、脊灰1型和脊灰3型达到血清保护性抗体滴度。
- BRV-PV组与Rotarix®组针对上述所有抗体的血清保护率差异均小于1%。
- 抗百日咳IgG几何平均浓度比值BRV-PV组 vs Rotarix®组为1.04(90%CI 0.90;1.19)。
关键数值与推荐
- 对白喉、破伤风、乙肝、Hib、脊灰1型和脊灰3型抗体,若BRV-PV组减Rotarix®组的血清保护率差异的双侧90%CI下限>10.0%,则支持非干扰。
- 对百日咳抗体,若几何平均浓度比值的双侧90%CI下限>0.5,则支持非干扰。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A newly developed bovine-human reassortant pentavalent vaccine (BRV-PV, ROTASIIL®) was tested for its potential effect on the immunogenicity of concomitantly administered EPI vaccines in infants in a randomized controlled study in India. METHODS: In this Phase III, multicenter, open label, randomized, controlled study, three doses of BRV-PV or two doses of Rotarix® and one dose of placebo were given to healthy infants at 6, 10, and 14 weeks of age. Subjects also received three doses of DTwP-HepB-Hib (diphtheria, tetanus, whole-cell pertussis, hepatitis B, and haemophilus influenzae type b conjugate - pentavalent vaccine) and oral polio vaccine concomitantly at 6, 10, and 14 weeks of age and a single dose of inactivated polio vaccine at 14 weeks of age. Blood samples were collected four weeks after the final vaccination to assess immune responses to all the vaccines administered. For diphtheria, tetanus, hepatitis B, Hib, polio type 1, and polio type 3 antibodies, non-interference was to be supported if the lower limit of the two-sided 90% confidence interval (CI) for the seroprotection rate difference for the BRV-PV group minus the Rotarix® group was >10.0%. For pertussis antibodies, non-interference was to be supported if the lower limit of the two-sided 90% CI for the ratio of geometric mean concentrations (GMCs) was >0.5. RESULTS: A total of 1500 infants were randomized to either BRV-PV (1125 infants) or Rotarix® (375 infants), of which 1341 completed the study as per the protocol. More than 97% of subjects achieved seroprotective antibody titres against diphtheria, tetanus, hepatitis B, Hib, polio type 1, and polio type 3 in both groups. The difference in seroprotection rates between the BRV-PV group and the Rotarix® group for all these antibodies was less than 1%. The ratio of GMCs of anti-pertussis IgG concentrations for the BRV-PV group versus Rotarix® was 1.04 [90% CI: 0.90; 1.19]. CONCLUSION: BRV-PV does not interfere with the immunogenicity of concomitantly administered routine infants vaccines.
引用
- Desai S, Rathi N, Kawade A, et al. Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine. Vaccine. 2018. PMID: 30104114. doi:10.1016/j.vaccine.2018.07.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。